Literature DB >> 8796403

Neonatal lupus erythematosus with congenital heart block and severe heart failure due to myocarditis and endocardititis of the mitral valve.

G Ferrazzini1, M Fasnacht, U Arbenz, R Seger, R Biedermann, B Simma, J Uehlinger, P Dangel, S Fanconi.   

Abstract

We report a case of neonatal lupus erythematosus (NLE) with congenital heart block and severe myocardial failure, which was followed from the 25th week of gestation because of fetal bradycardia. The child was delivered at the 37th week of gestation by elective cesarean section because of echocardiographically documented heart enlargement, pericardial effusion and moderate insufficiency of the mitral and tricuspid valves. In spite of immediate pacing, intubation and supportive treatment, the newborn developed progressive heart failure. Echocardiography showed endocarditis of the mitral valve and diffuse myocarditis. The heart failure resolved under steroid treatment. Our experience supports the early use of steroids in treating myocarditis due to NLE. Intrauterine steroid treatment in the presence of fetal hydrops and congenital heart block is discussed.

Entities:  

Mesh:

Year:  1996        PMID: 8796403     DOI: 10.1007/bf01712168

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  13 in total

1.  Fetal hydrops and congenital complete heart block: response to maternal steroid therapy.

Authors:  F Z Bierman; L Baxi; I Jaffe; J Driscoll
Journal:  J Pediatr       Date:  1988-04       Impact factor: 4.406

2.  Maternal connective tissue disease and congenital heart block. Demonstration of immunoglobulin in cardiac tissue.

Authors:  S E Litsey; J A Noonan; W N O'Connor; C M Cottrill; B Mitchell
Journal:  N Engl J Med       Date:  1985-01-10       Impact factor: 91.245

3.  Fetal survival after prednisone suppression of maternal lupus-anticoagulant.

Authors:  W F Lubbe; W S Butler; S J Palmer; G C Liggins
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

4.  Connective-tissue disease, antibodies to ribonucleoprotein, and congenital heart block.

Authors:  J S Scott; P J Maddison; P V Taylor; E Esscher; O Scott; R P Skinner
Journal:  N Engl J Med       Date:  1983-07-28       Impact factor: 91.245

5.  Intrauterine therapy for presumptive fetal myocarditis with acquired heart block due to systemic lupus erythematosus. Experience in a mother with a predominance of SS-B (La) antibodies.

Authors:  J P Buyon; S H Swersky; H E Fox; F Z Bierman; R J Winchester
Journal:  Arthritis Rheum       Date:  1987-01

6.  Maternal and fetal outcome in neonatal lupus erythematosus.

Authors:  A B McCune; W L Weston; L A Lee
Journal:  Ann Intern Med       Date:  1987-04       Impact factor: 25.391

7.  Anti-SS-A antibodies and fetal outcome in maternal systemic lupus erythematosus.

Authors:  R Ramsey-Goldman; D Hom; J S Deng; G C Ziegler; L E Kahl; V D Steen; R E LaPorte; T A Medsger
Journal:  Arthritis Rheum       Date:  1986-10

8.  Obstetric complications associated with the lupus anticoagulant.

Authors:  D W Branch; J R Scott; N K Kochenour; E Hershgold
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

Review 9.  Lupus anticoagulant and pregnancy.

Authors:  W F Lubbe; G C Liggins
Journal:  Am J Obstet Gynecol       Date:  1985-10-01       Impact factor: 8.661

10.  Neonatal lupus risk to newborns of mothers with systemic lupus erythematosus.

Authors:  M D Lockshin; E Bonfa; K Elkon; M L Druzin
Journal:  Arthritis Rheum       Date:  1988-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.